Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytodyn Inc
(OP:
CYDY
)
0.1470
-0.0030 (-2.00%)
Streaming Delayed Price
Updated: 2:37 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
576,040
Open
0.1500
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1500
Today's Range
0.1450 - 0.1539
52wk Range
0.1275 - 0.4180
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
Performance
YTD
-25.38%
-25.38%
1 Month
-12.50%
-12.50%
3 Month
-10.86%
-10.86%
6 Month
-8.13%
-8.13%
1 Year
-51.00%
-51.00%
More News
Read More
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
November 2023 Letter to Shareholders
November 03, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
January 17, 2023
Via
Benzinga
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 13, 2022
Via
Benzinga
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 27, 2022
Via
Benzinga
CytoDyn Announces Appointment of Additional Directors with Industry Experience
October 20, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
OTC Markets' Most Active Securities Sees A Shake-up In July
August 16, 2022
Via
Benzinga
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
August 11, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
August 10, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month
August 05, 2022
Via
Benzinga
Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June
July 18, 2022
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Via
Benzinga
CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY
March 18, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
February 14, 2022
Via
Benzinga
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From
CytoDyn Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.